Zelluna Doses First Patient in Phase 1 Trial, Raises NOK 58.2M — Zelluna ASA

Event summary

First patient dosed in Phase 1 ZIMA-101 study on 13 July 2026, evaluating ZI-MA4-1, the world’s first MAGE-A4-targeting TCR-NK therapy.
Independent Data Monitoring Committee recommended continued enrolment after favourable initial safety observations.
Raised NOK 58.2 million in June 2026 through private placement and retail offering.
Received NOK 16 million grant from the Research Council of Norway for the ZIMA-101 study.
Cash position of MNOK 86.2 as of 30 June 2026, expected to fund operations into Q3 2027.

The big picture

Zelluna’s progress in the ZIMA-101 trial marks a critical milestone in the development of TCR-NK therapies for solid cancers, a segment with significant unmet medical needs. The successful fundraising and grant funding underscore investor confidence in the company’s technology, while the favourable initial safety data positions Zelluna competitively within the biotech landscape. The strategic shift in board composition reflects a broader trend of institutional investors transitioning out of operational roles post-listing.

What we're watching

Clinical Progress: How the pace of patient recruitment and safety data from the ZIMA-101 trial will impact Zelluna’s valuation and strategic positioning in the TCR-NK space.
Financial Runway: Whether Zelluna’s current cash position will be sufficient to support operations until Q3 2027, given ongoing clinical and manufacturing expenses.
Pipeline Expansion: The extent to which Zelluna can leverage its proprietary TCR-NK platform to develop additional therapies beyond ZI-MA4-1.